As WHO Declares Swine Flu Pandemic, Vaccine Makers Could Soon Be Wallowing In Profits
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Demand is likely to increase for an A/H1N1 vaccine following a decision by the World Health Organization to declare a pandemic, even if the alert upgrade is unlikely to do much to speed up production already underway
You may also be interested in...
Start-Ups Set Sights on Flu
The swine flu/H1N1 pandemic presents a lucrative opportunity for drug developers and Big Pharmas won't be the only firms to capitalize on the sudden multibillion-dollar opportunity. There's evidence that the pandemic is driving investors to flu-focused biotechs as well. In this issue, we profile four emerging companies that hope to reap the rewards of what should continue to be a promising fund-raising environment for potentially novel flu therapies.
Korea Signs Deals With Roche, GSK For More Tamiflu, Relenza
SEOUL - Alarmed by the rising number of people infected with the H1N1 virus in neighboring Japan, and in Korea, the South Korean government has signed contracts recently to secure more of Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir)
Swine Flu Vaccines Likely to Be Shielded From Tort Claims
Vaccine manufacturers are ready to begin producing swine flu vaccines once the government gives them the nod to go forward. As they do so, they may be free from one worry: the risk of being sued for vaccine-related injuries